Immunic, Inc. · NASDAQ:IMUX
Immunic — Investor Day (May 2020)
169 slides from Immunic's investor day presentation, May 19, 2020
Slide 1: Inaugural R&D Day
Immunic THERAPEUTICS Inaugural R&D Day " NASDAQ: IMUX | May 19, 2020
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains "forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of his
Slide 3: Agenda
09:00 -09:10 | Welcome and Company Introduction 11:15 -11:25 | Introduction to IMU-935 09:10 -09:30 | Introduction to Lead Asset IMU-838 11:25 - 11:40 | Positioning of IMU-935 and Ongoing Phase 1 Program 09:30-10:00 | IMU-838 asa Potential Treatment Option for COVID-19 10:00 - 10:40 | Multiple Scler
Slide 4: Slide 4
Slide 5: Our Vision
Our Vision We are developing new therapies with best-in-class potential for the treatment of chronic inflammatory and autoimmune diseases. 5 | @immunie, nc. | 19.05.2020 f |mmunic
Slide 6: Leadership Team
Leadership Team Company is led by an experienced Renowned international management team board of directors Daniel Vit, Duane Nash, Duane Daniel Vit, tw PhD a MD, JD, MBA. I Nash, MD, a PhD. > (£0 & President Se cecutve 10, MBA > 0% of immunie chairman eeecutve Presidentof y y ee inne Andreas Hella K
Slide 7: Development Pipeline
Development Pipeline Barrier Function Program | Indication Target Preclinical Phase 1 Phase 2 Phase 3 IMU-838 Multiple Sclerosis DHODH ———E_——SET Ulcerative Colitis DHODH LEO EEE Crohn's Disease DHODH psc DHODH |, covio.18 DHODH == IMU-935, Psoriasis RORyt SSS Orphan Al Diseases RORyt == #£# #| imue
Slide 8: Mode of Action and Preclinical Summary
Mode of Preclinical Action Summary
Slide 9: Mode of Action
Mode of Action
Slide 10: IMU-838: Key Characteristics
IMU-838: Key Characteristics Oral small molecule Active moiety vidofludimus MW 355 g/mol IMU-838 is calciurn salt of vidofludimus Initially developed by 4SC AG as free acid form Acquired by Immunic in 2016 Chemical name (IUPAC): 2-(3-Fluoro-3”-methoxybiphenyl-4-ylcarbamoyl)-cyclopent-1-enecarboxylic
Slide 11: Mode of Action: DHODH Targeting Leads to Metabolic Stress
Mode of Action: DHODH Targeting Leads to Metabolic Stress in Metabolically Activated Cells Activated Lymphocyte Lymphocyte Insufficient CY erin "recycling “Stressed” Lymphocyte IMU-838, aly © Disease related activation © Activation of pyrimidine Metabolically silent eo de novo synthesis DHODH not im
Slide 12: Preclinical Summary
Preclinical Summary
Slide 13: IMU-838 Reduces Hyperactive Immune Cells
IMU-838 Reduces Hyperactive Immune Cells - IL-17F/IFNy High-Producers Hyperactive/high-affinity immune cells are specifically dependent on DHODH High metabolic turnover in high-affinity T cells High amounts of nucleotides for mRNA synthesis (up to 100-fold higher nucleotide demand for RNA synthesis
Slide 14: IMU-838 Provides a Less Inflammatory Environment
IMU-838 Provides a Less Inflammatory Environment Stopping a pro-inflammatory environment > Repression of pro-inflammatory cytokines. > Induction of some important anti-inflammatory cytokines {PerpherlBloed Moncrucasr Col, 2 Mixed LymphocrteRepctn ionmoretat, Paster UEGW 2018) 14 | © immunic, Inc. |
Slide 15: No General Antiproliferative Effects by IMU-838
No General Antiproliferative Effects by IMU-838 IMU-838 did not induce monocyto-, neutro- ces and leukopenia in a mouse model of SLE % of Total cells BePiacedo 10.0 G20mg " Indicating a significantly lower bone marrow toxicity 100mg compared to Cyclophosphamide 75. 300mg GCyp 5.0 IMU-838 has a natur
Slide 16: IMU-838 Demonstrates Dose-Dependent Activity in Rat EAE Model
IMU-838 demonstrates dose-dependent activity in rat EAE model Improvement of body weight for all doses tested Improvement of disease severity for 20and 60 mg/kg 5 1 15 2 2 30 5 10 15 2 2 3035 ‘Time after treatment start (days) Time after treatment start (days) a IMU-838 Demonstrated Activity in RRMS
Slide 17: Multiple Dosing of Vidofludimus in Humans
14 Day Multiple Dosing of 35 mg Vidofludimus in Humans — Corresponds to 30 mg IMU-838 p (ueymi) At35 mg vidofludimus (730 mg IMU-838), exposure in patients is continuously above the 90 % inhibition level (ICoq) OF IL-17F and IFNy ches —— i \ H yeee Organ distribution arene EE study in rats shows hig
Slide 18: Slide 18
Slide 19: ENTRANCE Study Safety
ENTRANCE Study Safety IBD Summary Comparison to Teriflunomide
Slide 20: ENTRANCE Study IBD
ENTRANCE Study IBD
Slide 21: ENTRANCE Study: Patient Population
ENTRANCE Study: Patient Population All patients with Almost equal distribution of steroid-dependent remission patients with CD and UC = Two prior failed attempts to discontinue Median duration of disease in CD 8.2 years corticosteroids and in UC 3.5 years = Currently on 20 mg prednisolone equivalent
Slide 22: ENTRANCE Study: Primary Efficacy Results
ENTRANCE Study: Primary Efficacy Results ic ENTRANCE Study:!"! Study performed with active moiety vidofludimus All patients failed two attempts to taper down steroids Open-label Primaryefficacy endpoint: steroid-free/steroid-reduced remission (week 12) [a] eringer eta, 2012, G3ercanerctogy 40:58, [2
Slide 23: Phase 1 Results
Phase 1 Results
Slide 24: IMU-838: Publication of Phase 1 Data
IMU-838: Publication of Phase 1 Data 24 | @immunic, nc. | 28.05 2020 Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects Andreas Muehler, Hella Kohlhof, Manfred Groeppel & Daniel Vitt European Journal of
Slide 25: IMU-838: Human Pharmacokinetic Profile
IMU-838: Human Pharmacokinetic Profile IMU-838 is orally bioavailable with linear pharmacokinetics Dose-linear pharmacokinetics Tmax 2-3 Hh after dosing Terminal elimination half-life ty, is roughly 30 hours Accumulation factor in multiple dosing is approximately 2 = No detrimental food effect * Inc
Slide 26: IMU-838: Population Pharmacokinetic Model
IMU-838: Population Pharmacokinetic Model (Based on Phase 1 Studies) * Lnfcone.) pg/ml, Dose Time (hes) Observed pharmacokinetic data from 40 mg once daily IMU-838 (14-day multiple ascending dose phase 1 study) and derived population PK model The prediction has been obtained by adjusting the paramet
Slide 27: Safety Summary
Safety Summary
Slide 28: IMU-838: Safety Summary
IMU-838: Safety Summary 9 g b Safety profile similarto placebo Current drug exposure summary No signal for hepatotoxicity Total exposure of more than approximately (and no higher risk of LFT elevations) 650 human subjects and patients No signal for neutropenia or alopecia Safe dose range for IMU-838
Slide 29: COMPONENT Trial: Publication of Safety Summary
COMPONENT Trial: Publication of Safety Summary The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study Andreas Muehler, Hella Kohlhof, Manfred Groeppel & Daniel Vitt Drugs in R&D ssw 11745886 upeR ess (9 Immunic 29. | @imm
Slide 30: COMPONENT Trial: Safety & Tolerability Data
COMPONENT Trial: Safety & Tolerability Data Infections & Infestations TEAEs (incidence > 2%) Vidofludimus 35 mg Placebo byMedDRA System Organ Class n=122 n=119 n % n % Total number of patients with probably related TEAEs 5 4 10 84 Gastrointestinal disorders 1 08 4 3.4 Investigations 0 0 3 25 Total n
Slide 31: COMPONENT Trial: Safety & Tolerability Data
COMPONENT Trial: Safety & Tolerability Data Hepatic Events & Elevation of Liver Enzymes Hepatotoxic TEAES Vidofludimus 35 mg Placebo by preferred Term n=122 n=119 n % n % Biliary Colic ° 0.0 1 08 Hepatic Pain 0 0.0 1 08 Hepatic Steatosis ) 0.0 d 08 Hepatocellular Injury 1 08 0 0.0 y-Glutamyl Transfe
Slide 32: IMU-838: Interim Dosing Analysis of Phase 2 Study in UC
IMU-838: Interim Dosing Analysis of Phase 2 Study in UC Established Broad Safe Dose Range (August 2019) Goal = Ineffective and/or intolerable IMU-838 dose(s) would be identified in this interim analysis based on all available clinical, endoscopic, biomarker, PD, and safety data = Performed by an unb
Slide 33: Comparison to Teriflunomide
Comparison to Teriflunomide
Slide 34: Teriflunomide Has a Safety Profile Not Expected From Selective DHODH Inhibition
Teriflunomide Has a Safety Profile Not Expected From Selective DHODH Inhibition ° 14mg [i Aubagio® 7 mg Placebo Adverse Event (Gesu) {n=1045) (n=997) Headache ALT increased* Diarrhea Alopecia’ Nausea _~ | Ei Es ka pom fF «| pom Fo | _asbago® (trtuncmid) Presebng Infrmation UUSFDA. Medical Review fer
Slide 35: Off-Target Effects: Kinase Inhibition by Teriflunomide
Off-Target Effects: Kinase Inhibition by Teriflunomide eriflunomide Teriflunomide is not rough level selective for DHODH, it | also inhibits kinases such as oe Ss PDGFR, Aurora A, FYN, LCK, Aurora A SSE JAK3, PIM and EGFR JaK3 re > <= Most common adverse 1k = events of EGFR inhibitors: ee skin disor
Slide 36: IMU-838: Pharmacokinetic Profile Well Suited for Once Daily Dosing
IMU-838: Pharmacokinetic Profile Well Suited for Once Daily Dosing Lacks need for accelerated elimination procedures known from teriflunomide IMU-838 Half-life: 30 hours in humans Accumulation factor: 2 Quick wash-out without need for elimination procedure bY BN + Oberserved Log (Concentration) Medi
Slide 37: COVID-19 Section Overview
Mode of Action Introduction and Antiviral Effect Preclinical Data Clinical Q&A Development COVID-19 Program
Slide 38: Slide 38
Slide 39: COVID-19 Cases per Million Inhabitants: A Comparison
COVID-19 Cases per Million Inhabitants: A Comparison Confirmed COVID-19 cases per one million population Total cases ‘22 | Belgium @) fF 4,401 Prevalence United States [I 3,009 o(©)2° of COVID-19 ° ° swiverland © TT 3.520 ote per capita ‘oh I 3507 sng: I 220 France () I 2.532 Portugal @ I 2.282 * ot
Slide 40: Is Vaccination Our Best Hope for the End of the Pandemic?
Is Vaccination Our Best Hope for the End of the Pandemic? More than 70 vaccine candidates are in development around the world, with at least five in preliminary testing in people. Current stage: Development 2 ‘of vaccine candidates and. Time frame unclear. 6-18 months. Maybe longer. £ spike protein(
Slide 41: The Waves of the Spanish Flu
The Waves of the “Spanish Flu” The figure shows weekly combined influenza and pneumonia mortality in the United Kingdom, 1918-1919. Deaths per 1,000 persons a a 629° 7R7 «= a2 AT MOND NG 12411 aS, 100 YEARS ACTER ANISH FLU:ISTHE WORLD READY FORTHE NEIT PANDEMIC? Pubihed by Gar Femegan on October 24%
Slide 42: The Need for Effective Therapies for COVID-19
The Need for Effective Therapies for COVID-19 An effective vaccine could be more than a year away, however it cannot be guaranteed that a vaccine provides full immunity from the disease Even with an available vaccine, effective drug treatments and therapies help ease the strain on overwhelmed health
Slide 43: COVID-19: The Therapeutic Challenge
COVID-19: The Therapeutic Challenge Stage 1 Stage 2 Stage 3 (Early Infection) (Pulmonary Phase) (Hyperinflammation Phase) Viral response phase Severity of illness ee ‘ aa nes iniannaors Time course Mild constitutional symptoms 5 ali Shortness of Breath Fever >99.6°F Hypoxia (Pa02/FI02<300mmH; Dry Co
Slide 44: Antiviral vs. Immunomodulatory Treatments
Antiviral vs. Immunomodulatory Treatments Viral Replication Immune Overstimulation Direct Antiviral Therapies Immunomodulators Example: Remdesivir Example: Tocilizumab “Nucleotide starving” we Virus-infected host cells Highly stimulated immune cells 44 | @tmmunic, ne. | 19.05.2020 & Immunic
Slide 45: Revised Concept of Antiviral Combinations Using IMU-838
Revised Concept of Antiviral Combinations Using IMU-838 — Combination of Virus and Host Cell Targeting Conventional IMU-838 antiviral therapies (DHODH inhibitor) Inhibit virus replication via viral targets Inhibits virus replication via host cell targets Potential synergistic effects in combination
Slide 46: Mode of Action and Antiviral Effect
Mode of Action and Antiviral Effect
Slide 47: Summary of Rationale for IMU-838 in COVID-19
Summary of Rationale for IMU-838 in COVID-19 Dual mode of action: orally available DHODH inhibitor with both, antiviral and anti-inflammatory effects Host-based mechanism: avoids dependence on specific viral proteins and, therefore, offers broad-spectrum antiviral activity Uninfected Virus Block of
Slide 48: Preclinical Data
Preclinical Data
Slide 49: IMU-838: Activity Against SARS-CoV-2 and Other Viruses
IMU-838: Activity Against SARS-CoV-2 and Other Viruses 49 | @immunie, nc. | 19.05.2020 IMU-838 is active against SARS-CoV-2 IMU-838 has shown broad- spectrum antiviral activity against different pathogenic viruses with ECso values in single digit UM range “ * imu-s3g ACY 4 hCMV Arenavirus SARS-CoV-2
Slide 50: IMU-838: SARS-CoV-2 Preclinical Testing
IMU-838: SARS-CoV-2 Preclinical Testing Collaboration partners in Germany and the United States IMU-838 demonstrated inhibition of SARS-CoV-2 replication Utah state University of Chicago @ raat @ Or. mils ‘A549-ACE2 cells (human lung epithelial cells, overexpressing ACE2 receptor) 9 iettten ox = Vir
Slide 51: IMU-838: Triple Attack on COVID-19
IMU-838: Triple Attack on COVID-19 IMU-838 attacks COVID-19 disease by three complementary mechanisms Bi Inhibition of virus replication by depletion of nucleotide pool 2 Insufficient first immune response due to SARS-CoV-2 encoded interferonantagonists Induction of innate immune response by DHODH i
Slide 52: Third Party Research Shows Synergistic Effect on Survival
Third Party Research Shows Synergistic Effect on Survival of Using Antiviral Drug in Combination with DHODH Inhibitor a ‘ongR eta bietal Mareh2oza207008 21 52 | @immunie, nc. | 19.05.2020 BALB/c mice were intranasal infected with AOOOPFU of A/WSN/33 virus and then intraperitoneal injected {i.p.) wit
Slide 53: Clinical Development Program
1 Q2e9 Clinical Development Program
Slide 54: Potential Advantages of DHODH Inhibitors
Potential Advantages of DHODH Inhibitors 54 | immune, nc. | 19.05.2020 Targeting the host provides broad-spectrum antiviral activity Blocking viral replication and independent of potential viral mutagenesis May act directly on the virus replication in the infected cells and in addition induce innate
Slide 55: Antiviral vs. Immunomodulatory Treatments
Antiviral vs. Immunomodulatory Treatments Viral Replication mulation COVID-19 co Mild ct Moderate Severe “08 Disease lle Disease Disease | Orme ne | s365a0%0 (9 Immunic
Slide 56: Modified WHO Ordinal Scale for Clinical Status
Modified WHO Ordinal Scale for Clinical Status Patient state Descriptor Score Uninfected or no longer No clinical or virological evidence of infection ° infectious Mild Disease Ambulatory, virus-positive, no limitation of activities 1 Ambulatory, us-positive, limitation of activities 2 Moderate Dise
Slide 57: Proposed Treatment Regimen of IMU-838 in COVID-19 Patients
Proposed Treatment Regimen of IMU-838 in COVID-19 Patients Treatment course of 14 days Initial loading dose of 45mg Further dosing of 22.5 mg BID Dayo Day1 Days 2 to 12 Day13 Time PM AM PM AM PM AM PM Number of tablets 2 1 1 1 a 1 1 Dose IMU-838 45 mg, 22.5mg 22.5mg 22.5mg 22.5mg 22.5mg 22.5mg # * *
Slide 58: Anticipated Pharmacokinetic Profile 22.5 mg BID
Anticipated Pharmacokinetic Profile 22.5 mg BID 14-day Treatment in Phase 2 IMU-838 in COVID-19 Patients 25 20 Proposed dosing = 15 regimen ensures 2 SARS-CoV-2 that therapeutic 8 2 10 EG levels of IMU-838 * are reached a EGo starting from first dose 0 o 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Slide 59: CALVID-1: Phase 2 Clinical Trial Design in COVID-19
CALVID-1: Phase 2 Clinical Trial Design in COVID-19 Prospective, multicenter, randomized, placebo-controlled, double-blind phase 2 clinical trial Active: 2x 22.5 mg IMU-838/day + investigator’s choice of standard-of-care therapy > BO Eligible my & 14 days treatment patients eraten > Control: 2x plac
Slide 60: CALVID-1: Study Population and Allowed Treatments
CALVID-1: Study Population and Allowed Treatments Study Population Confirmed SARS-CoV-2 infection Patients with moderate COVID-19 disease and clinical symptoms, defined as WHO clinical status 3 & 4 (hospitalized, not on invasive ventilation) a Standard exclusions for pre-existing severe renal, liver
Slide 61: CALVID-1: Study Endpoints
CALVID-1: Study Endpoints Primary Key Secondary Secondary Clinical Endpoint Endpoints Endpoints Proportion of patients Duration of ICU treatment Clinical improvement without any need for invasive — — ventilation 28-day all-cause mortality Duration of hospitalization 61 | Gimmunie, nc. | 19.05.2020 C
Slide 62: COVID-19 Q&A
Q&A COVID-19
Slide 63: Slide 63
Slide 64: Publication of Profile of IMU-838 for Indication MS
Publication of Profile of IMU-838 for Indication MS Vidofludimus calcium, a next generation , DHODH inhibitor for the Treatment of relapsing. ULTIPLE remitting multiple sclerosis ROSIS -Anceas Male, vey Pen’, Hela Kono, Mane Grppt, Dn it rd.2020,102129 Multiple Sclerosis and Related Disorders The in
Slide 65: Teriflunomide (Aubagio®)
Teriflunomide (Aubagio®) Global Sales Aubagio® in MS. Worldwide Sales (in £8) US Prescribing Information 2 * Aubagio® is indicated for the treatment of relapsing forms of 16 MS, to include clinically isolated syndrome, RRMS, and 14 active secondary progressive disease, in adults. " = The recommended
Slide 66: Concept of inflammatory mechanisms
Concept of inflammatory mechanisms a | Relapse-Related Inflammatory Mechanisms Influencing it may mainly be visible as decrease in annualized relapse rate (ARR) [z) Relapse-Independent Inflammatory Mechanism in RRMS local Systematicimmune Resolution Acute Injury SSE qe eI yew ons parenchymal damage
Slide 67: Robert Fox
Robert Fox MD, FAAN Staff Neurologist, Mellen Center for Multiple Sclerosis =p | Vice-Chair for Research, Neurological Institute Cleveland Clinic, Ohio
Slide 68: Phase 2 RRMS, Phase 2 UC, Phase 2a PSC Q&A
Phase 2 RRMS. Phase 2 UC Phase 2a PSC Q&A IMU-833
Slide 69: Impact of COVID-19 on Ongoing Clinical Programs for IMU-838
Impact of COVID-19 on Ongoing Clinical Programs for IMU-838 Patients with chronic diseases involving the immune No formal stop of enrollment for any study system are usually considered higher risk patients using IMU-838 for infections = However, enrollment has been slow for " Data indicate that MS a
Slide 70: Phase 2 RRMS
Phase 2 RRMS.
Slide 71: EMPhASIS: Phase 2 Study Overview in RRMS
EMPhASIS: Phase 2 Study Overview in RRMS Coordinating Investigator Robert Fox, MD (Cleveland Clinic) Main Treatment Period Population: RRMS With Relevant Disease Activity Male or female (18> age <55) RRMS diagnosis (Revised McDonald criteria 2017) Evidence of disease activity based on relapse and MR
Slide 72: EMPhASIS: Phase 2 Trial Design in RRMS
EMPHASIS: Phase 2 Trial Design in RRMS Main treatment p 24 weeks 30mg!IMU-838 — EoMT ————— 30 mgIMU-838 45mgiMU-838 — EoMT ————— 45 mg|MU-838 Placebo — EoMT Lk 30 mg IMU-838 45 mg IMU-838 Scr.exam. BLMRI — 30 0r45 mgiMU-838° — — 300r45 mgIMU-838> — — 30 0r45 mgIMU-838° — — 30 0r45 mgIMU-838° — EoT E
Slide 73: EMPhASIS: Schedule of MRI Examinations
EMPHASIS: Schedule of MRI Examinations Primary Endpoint All MRI Scans Will be Assessed Centrally by an Independent MRI Reading Center Only To evaluate the efficacy of 45 mg/day IMU-838 as compared to placebo based on the cumulative number of new combined unique active lesions at Week 24 Combined Uni
Slide 74: EMPhASIS: Secondary Endpoints
EMPhASIS: Secondary Endpoints MRI endpoints T2-and T1-lesion load T1-lesion load at Weeks 6, 12, 18and 24compared to Baseline Number of new Gd+, T2, and! lesions Proportion of patients without new Gd+ lesions over 24 weeks Relapse-related clinical endpoints Mean annualized relapse rate Proportion of
Slide 75: EMPhASIS: Enrollment Completed
EMPhASIS: Enrollment Completed As of October 10, 2019 enrollment is completed Study has enrolled 210 patients in four countries & . . Sq Recruitment Activity (Ukraine, Bulgaria, Romania, Poland) peeves | ‘| Centralized blinded MRI assessment done 2 by Siena Imaging i |, al on al I ii Fee Maris ard i
Slide 76: EMPhASIS: Enrollment and Discontinuations (Blinded)
EMPhASIS: Le set apai27, 2000 76 | immune, nc. | 19.08.2020 Enrollment and Discontinuations (Blinded) 210 patients randomized (Feb 2019 — Oct 2019) 1 patient withdrawn for personal reasons 209 patients received IMP 5 patients withdrawn for personal reasons 3 patients withdrawn due to lab abnormaliti
Slide 77: EMPhASIS: Current Study Status
EMPhASIS: Current Study Status oom 77 | @immunie, Inc. | 19.08.2020 No patient left in blinded treatment phase (initial 24-week period) Study is still completely blinded Currently monitoring is being performed in anticipation of database lock i] Top-line unblinded data is expected in Q3/2020 Phase 3
Slide 78: IMU-838: Preparation of Phase 3 Readiness
IMU-838: Preparation of Phase 3 Readiness Availability of large a > quantities of active gevelopmen* A 2 A Ss pharm aceutical ingredient includin procs eon fitted tO a in Q2/2 or i SS 8 for ne facturing isc 9 new Short phase 1 | New manufacturing process bioequivalence (roller compactor) that allows
Slide 79: IMU-838: Potential Positioning in RRMS
IMU-838: Potential Positioning in RRMS 1 2 Unique properties Suggestion of sustained known from activity even after DHODH inhibitors multiple prior DMT regarding disability progression 79. | @immunie, Inc. | 19.05.2020 3 Known protection against John Cunningham virus reactivations and resulting PML
Slide 80: Mode of Action is Highly Competitive for Slowing Disability Progression
1. Mode of Action is Highly Competitive for Slowing Disability Progression DHODH inhibitors are at least as effective as S1Ps on Disability Progression Example Phase 3 trial of Ponesimod vs. Teriflunomide Time to 12-week Confirmed Disability Accumulation Time to 24-week Confirmed Disability Accumula
Slide 81: Slide 81
Slide 82: Slide 82
Slide 83: Slide 83
Slide 84: Slide 84
Slide 85: Slide 85
Slide 86: Slide 86
Slide 87: Slide 87
Slide 88: Slide 88
Slide 89: Slide 89
Slide 90: Slide 90
Slide 91: Slide 91
Slide 92: Slide 92
Slide 93: Slide 93
Slide 94: Slide 94
Slide 95: Slide 95
Slide 96: Slide 96
Slide 97: Slide 97
Slide 98: Slide 98
Slide 99: Slide 99
Slide 100: Slide 100
Slide 101: Slide 101
Slide 102: Slide 102
Slide 103: Slide 103
Slide 104: Slide 104
Slide 105: Slide 105
Slide 106: Slide 106
Slide 107: Slide 107
Slide 108: Slide 108
Slide 109: Slide 109
Slide 110: Slide 110
Slide 111: Slide 111
Slide 112: Slide 112
Slide 113: Slide 113
Slide 114: Slide 114
Slide 115: Slide 115
Slide 116: Slide 116
Slide 117: Slide 117
Slide 118: Slide 118
Slide 119: Slide 119
Slide 120: Slide 120
Slide 121: Slide 121
Slide 122: Slide 122
Slide 123: Slide 123
Slide 124: Slide 124
Slide 125: Slide 125
Slide 126: Slide 126
Slide 127: Slide 127
Slide 128: Slide 128
Slide 129: Slide 129
Slide 130: Slide 130
Slide 131: Slide 131
Slide 132: Slide 132
Slide 133: Slide 133
Slide 134: Slide 134
Slide 135: Slide 135
Slide 136: Slide 136
Slide 137: Slide 137
Slide 138: Slide 138
Slide 139: Slide 139
Slide 140: Slide 140
Slide 141: Slide 141
Slide 142: Slide 142
Slide 143: Slide 143
Slide 144: Slide 144
Slide 145: Slide 145
Slide 146: Slide 146
Slide 147: Slide 147
Slide 148: Slide 148
Slide 149: Slide 149
Slide 150: Slide 150
Slide 151: Slide 151
Slide 152: Slide 152
Slide 153: Slide 153
Slide 154: Slide 154
Slide 155: Slide 155
Slide 156: Slide 156
Slide 157: Slide 157
Slide 158: Slide 158
Slide 159: Slide 159
Slide 160: Slide 160
Slide 161: Slide 161
Slide 162: Slide 162
Slide 163: Slide 163
Slide 164: Slide 164
Slide 165: Slide 165
Slide 166: Slide 166
Slide 167: Slide 167
Slide 168: Slide 168
Slide 169: Slide 169